1-50 of 71
Keyword: Alzheimer's disease
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles
Biochem Soc Trans (2019) 47 (5): 1557-1565.
Published: 23 October 2019
...Amy J. Tibbo; Gonzalo S. Tejeda; George S. Baillie Phosphodiesterases (PDEs) have long been considered as targets for the treatment of Alzheimer's disease (AD) and a substantial body of evidence suggests that one sub-family from the super-family of PDEs, namely PDE4D, has particular significance...
Articles
Biochem Soc Trans (2018) 46 (4): 891-909.
Published: 19 July 2018
... mitochondrial abnormalities in the two most common neurodegenerative diseases, Parkinson's disease and Alzheimer's disease. In addition, we discuss the main strategies which have been explored in these diseases to target the mitochondria for therapeutic purposes, focusing on mitochondrially targeted...
Articles
Biochem Soc Trans (2016) 44 (1): 185-190.
Published: 09 February 2016
... precursor protein (APP), the central molecule in Alzheimer's disease aetiology, as a novel interaction partner of a subunit of the PIKfyve complex, Vac14. Furthermore, it has been shown that APP modulates PIKfyve function and PI(3,5) P 2 dynamics, suggesting that the APP gene family functions as regulator...
Articles
Biochem Soc Trans (2015) 43 (5): 920-923.
Published: 09 October 2015
...Hongyun Li; Tim Karl; Brett Garner ATP-binding cassette transporter A7 (ABCA7) is highly expressed in the brain. Recent genome-wide association studies (GWAS) identify ABCA7 single nt polymorphisms (SNPs) that increase Alzheimer's disease (AD) risk. It is now important to understand the true...
Articles
Biochem Soc Trans (2014) 42 (6): 1543-1549.
Published: 17 November 2014
... specific substrates and play a pivotal role in the regulation of various cell functions, including metabolism, growth, differentiation and apoptosis. Therefore they represent an interesting molecular target for the treatment of several diseases, such as cancer and Alzheimer's disease. Adopting a structure...
Articles
Biochem Soc Trans (2014) 42 (5): 1316-1320.
Published: 18 September 2014
...Amy M. Birch Astrocytes were historically classified as supporting cells; however, it is becoming increasingly clear that they actively contribute to neuronal functioning under normal and pathological conditions. As interest in the contribution of neuroinflammation to Alzheimer's disease (AD...
Articles
Biochem Soc Trans (2014) 42 (5): 1291-1301.
Published: 18 September 2014
... Society 2014 Alzheimer’s disease amyotrophic lateral sclerosis glia Huntington’s disease neurodegeneration Parkinson’s disease Neuroglia, represented by highly heterogeneous population of non-excitable cells of ectodermal/neural (astroglia, oligodendroglia and NG-2 glia) and mesodermal...
Articles
Biochem Soc Trans (2014) 42 (5): 1321-1325.
Published: 18 September 2014
...Emma C. Phillips; Cara L. Croft; Ksenia Kurbatskaya; Michael J. O’Neill; Michael L. Hutton; Diane P. Hanger; Claire J. Garwood; Wendy Noble; Wendy Noble Increased production of amyloid β-peptide (Aβ) and altered processing of tau in Alzheimer's disease (AD) are associated with synaptic dysfunction...
Articles
Biochem Soc Trans (2014) 42 (4): 1001-1005.
Published: 11 August 2014
...Irundika H.K. Dias; Maria C. Polidori; Helen R. Griffiths Blood cholesterol levels are not consistently elevated in subjects with age-related cognitive decline, although epidemiological studies suggest that Alzheimer's disease and cardiovascular diseases share common risk factors. These include the...
Articles
Biochem Soc Trans (2014) 42 (2): 587-592.
Published: 20 March 2014
...Vanessa Flaten; Cyril Laurent; Joana E. Coelho; Ursula Sandau; Vânia L. Batalha; Sylvie Burnouf; Malika Hamdane; Sandrine Humez; Detlev Boison; Luísa V. Lopes; Luc Buée; David Blum AD (Alzheimer's disease) is the most prevalent form of dementia in the aged population. Definitive diagnosis of AD is...
Articles
Biochem Soc Trans (2013) 41 (6): 1495-1502.
Published: 20 November 2013
...MaryKate McBrayer; Ralph A. Nixon Early-onset FAD (familial Alzheimer's disease) is caused by mutations of PS1 (presenilin 1), PS2 (presenilin 2) and APP (amyloid precursor protein). Beyond the effects of PS1 mutations on proteolytic functions of the γ-secretase complex, mutant or deficient PS1...
Articles
Biochem Soc Trans (2013) 41 (6): 1583-1587.
Published: 20 November 2013
... Alzheimer's disease, the most common age-related dementia associated with impairments in learning and memory accompanied by neuroinflammation, oxidative stress and neurodegeneration. The present mini-review examines the evidence supporting the roles that ECs appear to play in Alzheimer's disease and the...
Articles
Biochem Soc Trans (2013) 41 (5): 1331-1334.
Published: 23 September 2013
...Carola Stockburger; Christopher Kurz; Konrad A. Koch; Schamim H. Eckert; Kristina Leuner; Walter E. Müller The metabolic enhancer piracetam is used in many countries to treat cognitive impairment in aging, brain injuries, as well as dementia such as AD (Alzheimer's disease). As a specific feature...
Articles
Biochem Soc Trans (2012) 40 (4): 681-686.
Published: 20 July 2012
...Norbert Zilka; Branislav Kovacech; Peter Barath; Eva Kontsekova; Michal Novák Pathological truncations of human brain proteins represent the common feature of many neurodegenerative disorders including AD (Alzheimer's disease), Parkinson's disease and Huntington's disease. Protein truncations...
Articles
Biochem Soc Trans (2012) 40 (4): 661-666.
Published: 20 July 2012
...Kurt R. Brunden; Carlo Ballatore; Virginia M.-Y. Lee; Amos B. Smith, III; John Q. Trojanowski Neurons within the brains of those with AD (Alzheimer's disease) and related neurodegenerative disorders, collectively termed ‘tauopathies’, contain fibrillar inclusions composed of hyperphosphorylated tau...
Articles
Biochem Soc Trans (2012) 40 (4): 693-697.
Published: 20 July 2012
... therapeutic interventions can target the most toxic tau species. 1 To whom correspondence should be addressed (email a.mudher@soton.ac.uk ). 17 5 2012 © The Authors Journal compilation © 2012 Biochemical Society 2012 Alzheimer's disease filament oligomer tangle tau tauopathy...
Articles
Biochem Soc Trans (2012) 40 (4): 641-643.
Published: 20 July 2012
...Efthimios M.C. Skoulakis; Amritpal Mudher It is an exciting time for tau researchers as it is now generally accepted that abnormal tau species are required to mediate the toxic effects of amyloid β-peptide oligomers in Alzheimer's disease. Tau may play multiple roles in neurophysiology and there...
Articles
Biochem Soc Trans (2012) 40 (4): 721-727.
Published: 20 July 2012
...Cora O'Neill; Aoife P. Kiely; Meghan F. Coakley; Sean Manning; Caitriona M. Long-Smith The quality control of protein homoeostasis deteriorates with aging, causing the accumulation of misfolded proteins and neurodegeneration. Thus, in AD (Alzheimer's disease), soluble oligomers, protofibrils and...
Articles
Biochem Soc Trans (2012) 40 (4): 698-703.
Published: 20 July 2012
... Correspondence may be addressed to either of these authors (email Guy.Lippens@univ-lille1.fr or Isabelle.Landrieu@univ-lille1.fr ). 28 2 2012 © The Authors Journal compilation © 2012 Biochemical Society 2012 Alzheimer's disease nuclear magnetic resonance (NMR) phosphorylation protein...
Articles
Biochem Soc Trans (2012) 40 (4): 677-680.
Published: 20 July 2012
... with parkinsonism linked to chromosome 17), affect alternative splicing of exon 10, encoding a microtubule-binding motif. Advanced RNA analysis methods have suggested that levels of exon 10-containing MAPT mRNA are elevated in Alzheimer's disease. Furthermore, the MAPT H1 haplotype, associated with...
Articles
Biochem Soc Trans (2012) 40 (2): 297-309.
Published: 21 March 2012
... dysregulation of Ca 2+ signals have been linked to some of the major diseases in humans such as cardiac disease, schizophrenia, bipolar disorder and Alzheimer's disease. 1 email michael.berridge@babraham.ac.uk 13 12 2011 © The Authors Journal compilation © 2012 Biochemical Society 2012...
Articles
Biochem Soc Trans (2012) 40 (1): 282-286.
Published: 19 January 2012
... the roles that they may play in neural processes, including differentiation, memory formation, circadian rhythm regulation, neurotransmitter/hormone release and the pathogenesis of neurodegenerative disorders associated with aberrant Ca 2+ signalling, such as Alzheimer's disease. 1 To whom...
Articles
Biochem Soc Trans (2011) 39 (4): 933-938.
Published: 20 July 2011
...Jonathan Gilley; Robert Adalbert; Michael P. Coleman Considering the many differences between mice and humans, it is perhaps surprising how well mice model late-onset human neurodegenerative disease. Models of Alzheimer's disease, frontotemporal dementia, Parkinson's disease and Huntington's...
Articles
Biochem Soc Trans (2011) 39 (4): 910-916.
Published: 20 July 2011
...Rita J. Guerreiro; John Hardy In the present review, we look back at the recent history of GWAS (genome-wide association studies) in AD (Alzheimer's disease) and integrate the major findings with current knowledge of biological processes and pathways. These topics are essential for the development...
Articles
Biochem Soc Trans (2011) 39 (4): 851-856.
Published: 20 July 2011
...Lindsay Graham; Calum Sutherland The analysis of the molecular development of AD (Alzheimer's disease) is technically challenging, due to the chronic nature of the disease, the lack of early and definitive clinical diagnosis, and the fact that the abnormal molecular pathology occurs in the brain...
Articles
Biochem Soc Trans (2011) 39 (4): 920-923.
Published: 20 July 2011
... formation of amyloid plaques is the central process in the development of the symptoms of Alzheimer's disease. However, most clinical trials in this area have been disappointing; therefore the attendees of the Models of Dementia: the Good, the Bad and the Future meeting were given the opportunity to openly...
Articles
Biochem Soc Trans (2011) 39 (4): 886-890.
Published: 20 July 2011
...Hannah Johnston; Herve Boutin; Stuart M. Allan Inflammation has long been proposed as having a role in AD (Alzheimer's disease), although it remains unclear whether inflammation represents a cause or consequence of AD. Evidence from the clinical setting in support of a role for inflammation in AD...
Articles
Biochem Soc Trans (2011) 39 (3): 819-822.
Published: 20 May 2011
...Ana M. Mata; María Berrocal; M. Rosario Sepúlveda AD (Alzheimer's disease) is an age-associated neurodegenerative disorder where the accumulation of neurotoxic Aβ (amyloid β-peptide) in senile plaques is a typical feature. Recent studies point out a relationship between Aβ neurotoxicity and Ca 2...
Articles
Biochem Soc Trans (2010) 38 (6): 1474-1478.
Published: 24 November 2010
...Katrijn Coen; Wim Annaert AD (Alzheimer's disease) is a neurodegenerative disease characterized by a gradual loss of neurons and the accumulation of neurotoxic Aβ (amyloid β-peptide) and hyperphosphorylated tau. The discovery of mutations in three genes, PSEN1 (presenilin 1), PSEN2 (presenilin 2...
Articles
Biochem Soc Trans (2010) 38 (4): 953-954.
Published: 26 July 2010
... pathology of the various behaviourally and neuropathologically distinct tauopathies, the mechanisms of tau toxicity and the potential functional interaction of tau and amyloid in Alzheimer's disease remain elusive. Nevertheless, novel observations regarding the various aspects of taumisregulation-dependent...
Articles
Biochem Soc Trans (2010) 38 (4): 973-976.
Published: 26 July 2010
... compilation © 2010 Biochemical Society 2010 aggresome Alzheimer's disease neurodegeneration neurofibrillary tangle protein aggregation tau Protein aggregation is a common pathological hallmark of many neurological disorders. In a subset of these diseases, including AD (Alzheimer's disease...
Articles
Biochem Soc Trans (2010) 38 (4): 996-1000.
Published: 26 July 2010
...Jean-Pierre Brion; Kunie Ando; Céline Heraud; Karelle Leroy NFTs (neurofibrillary tangles) in Alzheimer's disease and in tauopathies are hallmark neuropathological lesions whose relationship with neuronal dysfunction, neuronal death and with other lesions [such as Aβ (amyloid β-peptide) pathology...
Articles
Biochem Soc Trans (2010) 38 (4): 955-961.
Published: 26 July 2010
...Yipeng Wang; Sarika Garg; Eva-Maria Mandelkow; Eckhard Mandelkow Tau aggregation is a hallmark of several neurodegenerative diseases, including AD (Alzheimer's disease), although the mechanism underlying tau aggregation remains unclear. Recent studies show that the proteolysis of tau plays an...
Articles
Biochem Soc Trans (2010) 38 (4): 1001-1005.
Published: 26 July 2010
... (Alzheimer's disease)-like NFTs (neurofibrillary tangles) in an age-dependent manner. Since murine tau might interfere with the toxic effects of human mutant tau, we set out to analyse the phenotype of our Tg30tau model in the absence of endogenous murine tau with the aim to reproduce more faithfully a model...
Articles
Biochem Soc Trans (2010) 38 (4): 962-966.
Published: 26 July 2010
...Khalid Iqbal; Xiaochuan Wang; Julie Blanchard; Fei Liu; Cheng-Xin Gong; Inge Grundke-Iqbal Independent of the aetiology, AD (Alzheimer's disease) neurofibrillary degeneration of abnormally hyperphosphorylated tau, a hallmark of AD and related tauopathies, is apparently required for the clinical...
Articles
Biochem Soc Trans (2010) 38 (4): 981-987.
Published: 26 July 2010
... Biochemical Society 2010 Alzheimer's disease Drosophila microtubule mushroom body neuron phosphorylation tau Tau is a predominantly axonal microtubule-associated phosphoprotein [ 1 , 2 ]. In Alzheimer's disease and a variety of sporadic neurodegenerative disorders with distinct and...
Articles
Biochem Soc Trans (2010) 38 (4): 1006-1011.
Published: 26 July 2010
... Authors Journal compilation © 2010 Biochemical Society 2010 Alzheimer's disease heparin nuclear magnetic resonance spectroscopy (NMR spectroscopy) phosphorylation tau Deregulation of tau phosphorylation has been linked to the pathogenesis of AD (Alzheimer's disease). The aggregated tau...
Articles
Biochem Soc Trans (2010) 38 (4): 988-992.
Published: 26 July 2010
...Catherine M. Cowan; David Shepherd; Amritpal Mudher AD (Alzheimer's disease) is a neurodegenerative disorder characterized by the abnormal hyperphosphorylation and aggregation of the microtubule-associated protein tau and the misfolding and deposition of Aβ peptide. The mechanisms by which tau and...
Articles
Biochem Soc Trans (2010) 38 (4): 1012-1015.
Published: 26 July 2010
... possible that the hyperphosphoryation of tau may contribute to the pathogenesis of Alzheimer's disease by promoting the formation of neurofibrillary tangles from cytosolic tau, and also by inhibiting additional tau functions through disruption of its targeting to the plasma membrane. 1 To whom...
Articles
Biochem Soc Trans (2010) 38 (4): 993-995.
Published: 26 July 2010
...Frank M. LaFerla Aβ (amyloid β-peptide) and tau are the main proteins that misfold and accumulate in amyloid plaques and NFTs (neurofibrillary tangles) of Alzheimer's disease and other neurological disorders. Historically, because plaques and NFTs accumulate in diverse cellular compartments, i.e...
Articles
Biochem Soc Trans (2010) 38 (2): 539-544.
Published: 22 March 2010
... accumulation of Aβ (amyloid β-peptide), a central event in AD (Alzheimer's disease) synaptic dysfunctions. Structural alterations introduced by site-specific modifications linked to protein aging may affect Aβ production, polymerization and clearance, and therefore play a pivotal role in the pathogenesis of...
Articles
Biochem Soc Trans (2010) 38 (2): 466-470.
Published: 22 March 2010
...–42 have provided encouraging candidates for AD (Alzheimer's disease) medicines in animal models, although none have yet proved to be effective in human trials. We have been investigating approaches to treat systemic amyloidoses, conditions that show common features with some CNS (central nervous...
Articles
Biochem Soc Trans (2010) 38 (2): 545-551.
Published: 22 March 2010
...Ayodeji A. Asuni; V. Hugh Perry; Vincent O'Connor Hyperphosphorylation of the microtubule-associated protein tau is a significant determinant in AD (Alzheimer's disease), where it is associated with disrupted axonal transport and probably causes synaptic dysfunction. Although less well studied...
Articles
Biochem Soc Trans (2010) 38 (2): 564-570.
Published: 22 March 2010
...Catherine M. Cowan; Francis Chee; David Shepherd; Amritpal Mudher Axonal microtubules are essential for transport of materials to the synapse. Compromised microtubules and synaptic loss have been demonstrated in AD (Alzheimer's disease), which is believed to contribute to cognitive dysfunction...
Articles
Biochem Soc Trans (2009) 37 (5): 1126-1132.
Published: 21 September 2009
... proposed in cancer, Alzheimer's disease and HIV treatment. These numerous therapeutic roles elevate VPA to near ‘panacea’ level. Surprisingly, the mechanisms of action of VPA in the treatment of many of these disorders remain unclear, although it has been shown to alter a wide variety of signalling...
Articles
Biochem Soc Trans (2009) 37 (4): 692-696.
Published: 22 July 2009
...Hozefa Amijee; Jill Madine; David A. Middleton; Andrew J. Doig The aggregation of numerous peptides or proteins has been linked to the onset of disease, including Aβ (amyloid β-peptide) in AD (Alzheimer's disease), asyn (α-synuclein) in Parkinson's disease and amylin in Type 2 diabetes. Diverse...
Articles
Biochem Soc Trans (2008) 36 (6): 1299-1303.
Published: 19 November 2008
... (email bssdrb@bath.ac.uk ). 25 4 2008 © The Authors Journal compilation © 2008 Biochemical Society 2008 Alzheimer's disease amyloid precursor protein neurodegeneration Parkinson's disease prion synuclein transmissible spongiform encephalopathy (TSE) Two of the most...
Articles
Biochem Soc Trans (2007) 35 (5): 1219-1223.
Published: 25 October 2007
...M.J. Rowan; I. Klyubin; Q. Wang; N.W. Hu; R. Anwyl There is growing evidence that mild cognitive impairment in early AD (Alzheimer's disease) may be due to synaptic dysfunction caused by the accumulation of non-fibrillar, oligomeric Aβ (amyloid β-peptide), long before widespread synaptic loss and...
Articles
Biochem Soc Trans (2007) 35 (3): 571-573.
Published: 22 May 2007
...C. Dingwall; C. Dingwall The amyloidogenic processing pathway of the APP (amyloid precursor protein) generates Aβ (amyloid β-peptide), the major constituent in Alzheimer's disease senile plaques. This processing is catalysed by two unusual membrane-localized aspartic proteinases, β-secretase [BACE1...
Articles
Biochem Soc Trans (2007) 35 (2): 416-420.
Published: 20 March 2007
...D.M. Walsh; A.M. Minogue; C. Sala Frigerio; J.V. Fadeeva; W. Wasco; D.J. Selkoe Overwhelming evidence indicates that the Aβ (amyloid β-peptide) plays a critical role in the pathogenesis of Alzheimer's disease. Aβ is derived from the APP (amyloid precursor protein) by the action of two aspartyl...